Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Tazemetostat in Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation

NCT03456726 is registered in ClinicalTrials.gov with Eisai Co., Ltd. as lead sponsor.

NCT NCT03456726
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03456726 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Tazemetostat in Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation
Lead sponsor
Eisai Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
April 9, 2018
Completion date
December 17, 2021
Enrollment
20 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory b-cell non-hodgkin's lymphoma